Marinus Pharmaceuticals Presents Clinical Data of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Marinus Pharmaceuticals Presents Clinical Data of Ganaxolone in Pediatric Epilepsies at Antiepileptic Drug and Device Trials XIII Conference

RADNOR, Pa., May 18, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS ), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric therapeutics, announced that Gail M. Farfel, Ph.D., Chief Clinical and Regulatory Officer of Marinus, presented clinical data on ganaxolone in drug-resistant pediatric epilepsies at the Antiepileptic Drug and Device Trials (AED) XIII conference on Friday, May 15, 2015.

Dr. Farfel shared clinical data on ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, for the treatment of pediatric seizure disorders in children aged 4 months through 15 years. Across the one double-blind and four open-label studies of refractory pediatric subjects, approximately two thirds of subjects experienced improvements in seizures and one third of subjects experienced improvements of 50% or greater from baseline seizure frequency. The adverse event profile of ganaxolone in pediatric studies is similar to that seen in adults, without evidence of unique, clinically meaningful adverse events specific to the pediatric population. Most of the adverse events reported in the pediatric studies were mild or moderate in severity and expected based on ganaxolone pharmacology and the age group under evaluation.

In addition, during the presentation, Dr. Farfel highlighted the promising potential ganaxolone holds for additional pediatric seizure disorders, such as PCDH19 female pediatric epilepsy, a rare and serious epileptic syndrome caused by a mutation of the protocadherin 19 (PCDH19) gene and characterized by early-onset cluster seizures, cognitive and sensory impairment of varying degrees, and behavioral disturbances. Earlier this year, Marinus received orphan drug designation from the United States Food and Drug Administration for PCDH19 female epilepsy and initiated a multicenter, open-label, proof of concept Phase 2 clinical trial evaluating the safety and efficacy of ganaxolone in this condition. Further information about the Phase 2 study can be found on ClinicalTrials.gov , using Identifier NCT02358538.

"In clinical studies, ganaxolone has consistently demonstrated the ability to reduce seizure frequency in pediatric patients," Dr. Farfel commented. "Based on ganaxolone's rational design and our evolving understanding of genetic contributions to epileptic syndromes, we believe the drug offers the potential to significantly reduce seizure frequency in girls with PCDH19 female epilepsy and other seizure disorders and provide these children with a treatment option that targets the pathophysiology of their condition."

About Ganaxolone

Ganaxolone is a small molecule that is a synthetic analog of allopregnanolone, an endogenous neurosteroid produced in the central nervous system that modulates GABA, the major brain inhibitory neurotransmitter. Ganaxolone was designed to have similar GABA modulation effects to allopregnanolone without unwanted steroidal side effects. Ganaxolone and allopregnanolone differ from other GABA A agents by interacting at both synaptic and extrasynaptic GABAAreceptor binding sites that are located both within and outside the GABA synapse. Ganaxolone's activation of the extrasynaptic receptor is a unique mechanism that, in addition to other effects, increases tonic GABA signaling effects that we believe differentiates it from other available drugs that increase GABA levels in the brain. Preclinical studies provide evidence that the GABA modulatory activity of ganaxolone is responsible for its anticonvulsive activity in epileptic seizures and its antianxiety effects in animal models of other neuropsychiatric disorders. Ganaxolone is being developed in three dose forms; oral capsule, oral liquid suspension, and intravenous formulation in order to bring convenient dosing to a variety of clinical situations.

About PCDH19 Female Pediatric Epilepsy

PCDH19 female pediatric epilepsy is a serious and rare epileptic syndrome that affects approximately 15,000-30,000 females in the United States. The condition, which is caused by an inherited mutation of the protocadherin 19 (PCDH19) gene, located on the X chromosome, is characterized by early-onset cluster seizures, cognitive and sensory impairment of varying degrees, and behavioral disturbances. The PCDH19 gene encodes a protein, protocadherin 19, which is part of a family of molecules supporting the communication between cells in the central nervous system. In case of mutation, protocadherin 19 may be malformed, reduced in its functions or not produced at all. The abnormal expression of protocadherin 19 is associated with occurrence of seizures beginning in the early years of life, mostly focal clusters of seizures that last from one day to weeks. Often, but not always, the syndrome is also associated with a cognitive impairment of varying nature, and behavioral or social disorders with autistic traits. Currently, there are no approved therapies for PCDH19 female pediatric epilepsy.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate for the treatment of seizure disorders in adults and children with epilepsy is ganaxolone. Ganaxolone is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone (known for its anticonvulsive and antianxiety effects) and was designed to avoid hormonal side effects associated with endogenous neurosteroids. The Company is currently conducting a multi-national, randomized, placebo-controlled, Phase 3 clinical trial to evaluate ganaxolone as adjunctive treatment of partial-onset seizures in adults. Ganaxolone is also being studied in a Phase 2 proof-of-concept clinical study for the treatment of the rare, genetic disorder, PCDH19 female pediatric epilepsy. To complement the existing formulations and to provide continuity of care, the Company is developing an IV formulation of ganaxolone for use in the hospital setting to control epileptic seizures. In addition, ganaxolone is being evaluated in a Phase 2 proof-of-concept investigator-sponsored clinical trial as a treatment for behaviors in Fragile X Syndrome. For additional information, please visit the Company's website at www.marinuspharma.com .

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Words such as "may", "will", "expect", "anticipate", "estimate", "intend", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.  Examples of forward looking statements contained in this press release include, among others, statements regarding our expectations regarding our development plans for our product candidate, including, potential for orphan designation, optimizing a product's formulation, the clinical trial testing schedule, the ability to complete enrollment in our clinical trials, timing for availability and release of data, the safety, potential efficacy and therapeutic potential of our product candidate and our expectation regarding the sufficiency of our working capital. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.  Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical trials, the timing of the clinical trials, enrollment in clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters, including the development of formulations of ganaxolone, that could affect the availability or commercial potential of our drug candidates.  Marinus undertakes no obligation to update or revise any forward-looking statements.  For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.          

Company: Lisa M. Caperelli Senior Director, Investor Relations & Corporate Communications Marinus Pharmaceuticals, Inc. 484-801-4674 Media Contact: Tiberend Strategic Advisors, Inc. Amy S. Wheeler 646-362-5750

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 109

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 109

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 97

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading

Top 5 Most Recently Viewed Articles

Ready Capital Corporation's 2024 Results Overview & Future Insights

Updated Category News Views 176

Ready Capital Corporation's Upcoming Financial Results Ready Capital Corporation (NASDAQ: RC) is poised to share its financial results for the fourth quarter and the full year of 2024. This significant announcement is expected to take place before the opening bell of the New York Stock Exchange on the designated release date. Investors and interested parties are eagerly...

Continue Reading
Nano-X Faces Securities Suit, Investors Alerted

Updated Category News Views 32

Legal Tsunami Hits Nano-X Imaging If there’s one thing that makes investors' hairs stand on end, it’s the words 'class action lawsuit.' And now, it's swirling around Nano-X Imaging Ltd. (NASDAQ: NNOX) like a tempest. The DJS Law Group has taken the lead, lighting the legal torches on claims that Nano-X fed investors a cocktail of misleading statements regarding its...

Continue Reading
Novo Nordisk A/S Shareholders: Take Action on Recent Allegations

Updated Category News Views 218

Understanding the Novo Nordisk A/S Class Action Opportunity Recent developments have led to significant scrutiny of Novo Nordisk A/S, a major player in the pharmaceutical industry. For shareholders, this highlights a crucial opportunity to engage in a class action lawsuit regarding alleged misleading statements about the company's CagriSema weight loss study results....

Continue Reading
Investors of Inspire Medical Systems Should Act Before Deadline

Updated Category News Views 288

Important Deadline for Inspire Medical Systems Investors Investors of Inspire Medical Systems, Inc. are reminded that a critical deadline is approaching for those who purchased securities. The firm Kirby McInerney LLP has encouraged investors to take action as they seek the lead plaintiff role in a federal securities class action. About the Legal Proceedings This lawsuit...

Continue Reading
Nicholas Wealth's Impressive $GIAX Distribution Yield Announcement

Updated Category News Views 88

Recent Announcement from Nicholas Wealth Management Nicholas Wealth, renowned for its commitment to delivering actively managed income ETFs, has made an exciting announcement regarding its latest distribution. The Nicholas Global Equity and Income ETF (GIAX) will offer investors a substantial monthly distribution yield of an impressive 24.00%. This announcement is...

Continue Reading